phd programs in regenerative medicine

• Student/Faculty Portal
• Learning Hub (Brightspace)
• Continuous Professional Development

Regenerative Sciences

Regenerative sciences track.

faculty spanning multidisciplinary departments

education in discovery, clinical translation, and application of regenerative solutions

Guaranteed 5-year internal fellowship

includes full tuition, stipend and benefits

Seeking to spur development of innovative medical breakthroughs, Mayo Clinic Graduate School of Biomedical Sciences, in partnership with the Center for Regenerative Biotherapeutics , started one of the nation's first doctoral research training programs in regenerative sciences.

Regenerative medicine is transforming clinical practice with the development of new therapies, treatments and surgeries for patients with chronic conditions, debilitating injuries and degenerative diseases. Advances in developmental and cell biology, immunology, and other fields unlock new opportunities for innovative breakthroughs for the next generation of regenerative diagnostic and therapeutic medical solutions.

The Regenerative Sciences (REGS) Ph.D. track at Mayo Clinic is a transdisciplinary Ph.D. Program designed to prepare the next generation of scientists to accelerate the discovery, translation, and application of cutting-edge regenerative diagnostics and therapeutics. The REGS Ph.D. track builds on the existing Mayo Clinic Regenerative Sciences Training Program (RSTP) to now offer in-depth curriculum and advanced training opportunities. 

The Regenerative Sciences Track places a significant emphasis on laboratory-based research training. Laboratory research is complemented with both core and track-specific courses, as well as advanced courses on current topics in regenerative science and medicine.

The regenerative sciences curriculum encompasses the full spectrum of regenerative science topics, including molecular and cell biology, stem cell biology, developmental biology, tissue engineering, biomaterials and nanomedicine, genome editing and gene therapies, regulatory and translational science, product development, biomanufacturing, entrepreneurship and more.

Students in Regenerative Sciences join a close-knit community of learners, are provided unique hands-on- experiences and collaborate with some of the brightest minds in the field.

See the full Regenerative Sciences Track curriculum (PDF)

Graduates of the Regenerative Sciences Ph.D. track will be integral to forming the multidisciplinary workforce needed to drive the future of health care at Mayo Clinic and across the world.

Learn more:  What is Regenerative Medicine - Mayo Clinic Radio

Focus areas

• Molecular and epigenetic mechanisms of stem and progenitor cell proliferation and differentiation, as well as tissue degeneration and regeneration
• Immune responses to viral insult and tissue healing
• Gene editing for cell therapy applications and to alter disease progression
• Extracellular vesicles in disease progression and for tissue regeneration
• Tissue engineering and bioengineering of novel therapies, including 3-D printing, electrospinning, and advanced biomanufacturing 

Mayo Clinic is an incredible place for doctoral training in regenerative science. The interdisciplinary strategy here allows research and courses to be tailored according to each student’s interests and ability. Moreover, Mayo Clinic provides a wealth resource to develop collaborations within the institution, which will offer students more ways to communicate and promote students to achieve their personal goals.

Shan Gao Ph.D. student, Regenerative Sciences Track

Mayo Clinic provides unparalleled access to world-renowned clinicians and researchers all focused on clinically relevant research. Mayo Clinic’s Center for Regenerative Medicine permeates throughout the institution. Thus, the REGS program gives students the necessary experience and knowledge to drive future research in restoring form and function in any field of medicine.

Armin Garmany M.D.-Ph.D. student, Regenerative Sciences Track

The study of Regenerative Sciences (REGS) at Mayo Clinic is unparalleled. Students are funded to study cutting-edge biomedical science in their domain of interest with plentiful opportunities to translate benchside discoveries to the patient bedside and beyond. I chose Mayo Clinic's REGS program to join its community of researchers, practitioners, and entrepreneurs who everyday advance the science and practice of regenerative medicine and bring new regenerative solutions to the world.

Samuel Buchl Ph.D. student, Regenerative Sciences Track

The Regenerative Sciences Ph.D. track at Mayo Clinic thoroughly equips students to be leaders in biomedical research through an unmatched curriculum of multidisciplinary science and world-class research training. REGS is a collaborative and supportive program in a promising field of medicine that provides the foundational skills to pipeline research to patient care.

Delaney Liskey Ph.D. student, Regenerative Sciences Track

Thesis topics

Current students thesis topics.

• "Targeted Regenerative Therapies for Heart Failure Susceptibility," Armin Garmany (Mentor: Andre Terzic, M.D., Ph.D.)
• "Novel Look Into the Crude Stromal Vascular Fraction (SVF) from Human Adipose-Derived Tissue and Its Role in Regulating the Self-Renewing Capacity of Brain Tumor-Initiating Cells," Rawan Alkharboosh (Mentor: Alfredo Quinones-Hinojosa, M.D.)
• "Tissue Quality in Existing and Emerging Treatments for Osteoarthritis," Katherine Arnold (Mentor: Jennifer Westendorf, Ph.D.)
• "Harnessing the Mesenchymal Stem Cell Secretome to Target Alpha-Synuclein-Associated Dysfunction in Parkinson's Disease," Jeremy Burgess (Mentor: Pamela McLean, Ph.D.)
• "Retinal Neuroprotection Properties of an ATP-Sensitive Potassium Channel Opener," Catherine Knier (Mentor: Michael Fautsch, Ph.D.)
• "Towards a Subcutaneous Combination Biodevice for the Treatment of Type 1 Diabetes," Ethan Law (Mentor: Quinn Peterson, Ph.D.)
• "Modulation of CART Cell Activation to Enhance Antitumor Response via CRISPR-mediated Gene Editing and Combined Immunotherapy," Claudia Manriquez Roman (Mentor: Saad Kenderian, M.B., Ch.B.)
• "Systems Biology for Engineering Regenerative Immunotherapies in Precision Neuro-oncology," Dileep Monie (Mentors: Hu Li, Ph.D. and Richard Vile, Ph.D.
• "APOE2 Effects on Central and Peripheral Vasculature," Francis Shue (Mentor: Guojun Bu, Ph.D.)
• "Engineering of Antiviral Extracellular Vesicles," Amanda Terlap (Mentor: Atta Behfar, M.D., Ph.D.) 
• "Glycome of Breast Cancer-Derived Extracellular Vesicles in Metastasis," Sierra Walker (Mentor: Joy Wolfram, Ph.D.)
• "Bidirectional Interactions Between Stem Cell Populations of the Subventricular Zone and Glioblastoma," Emily Norton (Mentor: Hugo Guerrero Cazares, M.D., Ph.D.)
• "Measles Virus Vector for Gene Editing and Reprogramming of Human Fibroblasts," Ramya Rallabandi (Mentor: Patricia Devaux, Ph.D.)
• "Precise Genetic Engineering of Human Primary Cells for Cell Therapy-Based Applications," (Mentor: Stephen Ekker, Ph.D.)

Recent graduates thesis topics

• "Epigenetic Control of the Architectural and Trophic Functions of Mesenchymal Stem Cells in Musculoskeletal Tissue Regeneration Therapies," (Mentor: Andre van Wijnen, Ph.D.)
• "Metabolic Regulation of Muscle Stem Cells," (Mentor: Jason Doles, Ph.D.)
• "Purified Exosome Product Enhances Neovascularization in Peripheral Arterial Disease," (Mentors: Atta Behfar, M.D., Ph.D. and Andre Terzic, M.D., Ph.D.)
• "Antigen Presentation by CNS-Resident Microglia and Macrophages is Required for Antigen-Specific CD8 T Cell Responses in the Brain Following Viral Challenge," (Mentor: Aaron Johnson, Ph.D.)

Meet the director

Training opportunities extend from fundamental science principles through laboratory skills and hands-on experiences. Students will also have the opportunity to develop an understanding of national and international regulatory agencies, and business requirements and procedures needed to implement the discovery, translation, application pipeline for new regenerative technologies.

We are excited to provide a program of training that will serve as an incubator to develop the next generation of leaders in regenerative science and medicine.

Isobel Scarisbrick, Ph.D. Regenerative Sciences Track Director Professor of Physical Medicine & Rehabilitation Phone: 507-284-0124 Email: [email protected] See research interests

Browse a list of Regenerative Sciences Track faculty members

Frontier research and innovative teaching at the interface of biology and medicine

HSCRB Faculty Recognized for their Excellence in Undergraduate Teaching

Two hscrb faculty members were awarded honors for their work instructing undergraduates..

Fei Chen Wins 2024 Star-Friedman Challenge for Promising Scientific Research

The challenge provides seed funding for novel research in the physical or social sciences, with an emphasis on new directions that might not otherwise be supported through traditional funding channels., hscrb research, combating disease and tissue degeneration and improving human health., related links.

• Our Research
• Faculty and Labs

HSCRB Education

The best place to learn about stem cell science, at the graduate and undergraduate level..

• Undergraduate Students
• Graduate Students

HSCRB Introduces New Postdoc Professional Development Series

WHAT ARE YOU LOOKING FOR?

Key searches, development, stem cells and regenerative medicine, about the development, stem cells and regenerative medicine phd program.

The goal of the Ph.D. program in Development, Stem Cells, and Regenerative Medicine is to train the next generation of investigators in the history and practice of developmental and stem cell biology. The ultimate aim is to understand how the genomes of animals are translated into complex morphological forms, and to apply this basic knowledge to the emerging field of regenerative medicine. Mutlidisciplinary, collaborative research teams and close and regular contact between participating faculty and students creates and exciting and highly instructive environment.

Learn More!

Complete the form below for information on our graduate programs. Your journey towards a rewarding academic experience starts here!

IU School of Medicine launches new regenerative medicine PhD program aimed at workforce development

IU School of Medicine Jan 05, 2021

Chandan Sen, PhD

INDIANAPOLIS— Indiana University School of Medicine is excited to announce a new PhD program in regenerative medicine and technologies, a rapidly growing discipline which will shape the future of health care. The new PhD program will train next generation leaders who will contribute to the much-required, skilled workforce across the country and in Indiana. The program is expected to make a major economic impact through training new leaders in the field.

“This program is interdisciplinary in nature and is primarily focused on skilled workforce development to shape the future of regenerative medicine,” said Chandan Sen, PhD, director of the Indiana Center for Regenerative Medicine and Engineering (ICRME), associate vice president of research for IU School of Medicine and distinguished professor with the Department of Surgery . Sen also leads the regenerative medicine and engineering scientific pillar of the IU Precision Health Initiative. “It provides opportunities for industry internships and will meet the growing market demand in the regenerative medicine field.”

Regenerative medicine is an innovative new branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues. The field includes the generation and use of cell/tissue reprogramming, therapeutic stem cells, tissue engineering and the production of bioartificial organs. A drug is eligible for regenerative medicine advanced therapy (RMAT) designation by the United States Federal Drug Administration (FDA), as described in Section 3033 of the 21 st Century Cures Act. The new PhD program will be one of only six regenerative medicine PhD programs in the country and the second with an industry emphasis.

“Our goal is to have a limited size class made up of students from a variety of backgrounds,” Sen said. “There could be people coming from a biomedical engineering background, material science, biotechnology or many other areas of expertise.”

According to PR Newswire, the global regenerative medicine industry was valued at $35 billion in 2019. By 2025, it’s expected to grow to over $124 billion. Central Indiana is a growing hub for the field, with several Indiana-based companies in need of a greater regenerative medicine workforce. Six of these companies—Eli Lilly and Company, Cook Biotech-Cook Regentec, Roche, BioCrossroads, Ossium Health, Inc. and Techshot—are supporting the new PhD program by providing internship opportunities for students.

“Regenerating or engineering components of the body with therapeutic intent is a new horizon in medicine and will change the business of healthcare in general,” Sen said. “Our goal is to equip people to assume leadership positions to assemble new programs and define this new future of health care.”

The addition of this program will help continue to grow IU School of Medicine’s leadership in the field of regenerative medicine and engineering—giving learners an opportunity to discover the field at the earliest stages of their careers.

“IU School of Medicine is proud to be a leader in the growing field of regenerative medicine and engineering,” said Jay L. Hess, MD, PhD, MHSA , dean of IU School of Medicine and IU’s executive vice president for university clinical affairs. “This new program will help us address the major shortage of working professionals in this specialty. Students will become skilled in regenerative medicine-based innovations, regulatory science and supply chain management, making major contributions to the state’s economy and becoming leaders in the field on a statewide, national and global level.”

The program is part of the Indiana Center for Regenerative Medicine and Engineering, which is housed in the IU School of Medicine Department of Surgery . The center is a national leader in the areas of tissue nanotransfection, wound therapy, cell-based therapies, military medicine and more. There will be ample opportunities to work on research projects for students with an interest in these areas.

Learn more about the PhD in regenerative medicine program , including information on the curriculum and how to apply.

IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability.

SEARCH THE NEWSROOM

Subscribe to the news.

We've added you to our mailing list!

Sorry, there was a problem

Media Contacts

Related news.

• Schools & departments

Regenerative Medicine PhD

Awards: PhD

Study modes: Full-time, Part-time

Funding opportunities

Programme website: Regenerative Medicine

Upcoming Introduction to Postgraduate Study and Research events

Join us online on the 19th June or 26th June to learn more about studying and researching at Edinburgh.

Choose your event and register

Research profile

Research excellence.

The Centre for Regenerative Medicine (CRM) is a world leading research centre based at the University of Edinburgh’s Institute for Regeneration and Repair.

Our scientists and clinicians study stem cells, disease and tissue repair to advance human health. By better understanding how stem cells are controlled and how diseases develop in a lab environment, we hope to find new ways to treat patients.

Our research is aimed at developing new treatments for major diseases including cancer, heart disease, diabetes, degenerative diseases such as multiple sclerosis and Parkinson's disease, and liver failure.

The Centre houses 25 research groups and has a staff of more than 270 scientists, graduate students, support and ancillary staff.

Research themes

Our work is currently organised into five themes. To promote collaboration within the Centre, we adopt a flexible approach to these themes, with each Principal Investigator (PI) having one or more secondary affiliations.

Two themes focus on fundamental research:

• pluripotency and iPS
• lineage and cell specification

The other three themes aim to translate fundamental research discoveries into clinical programmes relevant to brain, blood and liver diseases and to tissue repair.

The Centre has strong collaborative links to other centres within the University, such as the Euan MacDonald Centre for MND Research, the MS Centre and the Roslin Institute.

We also invest in technological development in all areas.

Training and support

Training within the Centre is provided through a structured series of seminars and literature reviews, in addition to the laboratory and scientific research skills training provided to you by your supervisors.

Many of our PhD students are involved in collaborative projects that provide cross-disciplinary experience and/or promote translation into the biotechnology or clinical fields.

How will I learn?

Our programme includes short courses taught by basic and clinical stem cell scientists, providing a state-of-the-art theoretical background in a variety of areas relating to regenerative medicine including:

• developmental biology
• pluripotent and tissue stem cell biology
• degeneration and regeneration of adult tissues
• genetic engineering
• bioinformatics

We provide specialist lectures and short practical modules covering key technologies, including:

• DNA analysis and genetic engineering
• flow cytometry

In Year 1, you will participate in a weekly Centre for Regenerative Medicine ( CRM ) Postgraduate Discussion Group led by CRM group leaders. These discussion groups aim to widen your knowledge of stem cell and regenerative medicine research and to enhance your ability to critically review the literature in this field.

In addition to the taught components and research project, you will participate in a number of activities, including:

• regular lab meetings of your research group
• an internal seminar series
• seminars by visiting national and international speakers
• Journal Club
• poster presentations
• Three Minute Thesis presentation session.

Generic and transferable skills training is provided through the University's Institute for Academic Development (IAD).

• Institute of Academic Development

Since 2011, the Centre has been housed in a new, specially designed building that provides high quality research facilities, including:

• state of the art centralised cell culture facility for isolation and culture of primary and established cell lines including embryonic and induced pluripotent stem cells
• clinical-grade GMP cell culture facility
• specific pathogen free animal facility
• transgenic service covering derivation and provision of mouse embryonic stem cells, blastocyst injection, morula aggregation and production of defined genetic alterations
• ultrasound micro-injection equipment
• flow cytometry service consisting of a suite of cell sorters and analysers operated by facility staff that can be operated by users following comprehensive training
• a recently established single cell genomic analysis service using a 10x Genomics Chromium Controller
• quantitative real-time polymerase chain reaction equipment
• Fluidigm Biomark and CellPrep for single cell transcriptomics

Imaging facilities

We also have imaging facilities, including:

• standard compound microscopy
• widefield, confocal, and lightsheet microscopes
• high-content and timelapse imaging

The facility has dedicated imaging managers and offers two high-end workstations for bio-image processing and analysis.

Take a virtual tour of our facilities at the Centre for Regenerative Medicine:

• Virtual tour

Entry requirements

These entry requirements are for the 2024/25 academic year and requirements for future academic years may differ. Entry requirements for the 2025/26 academic year will be published on 1 Oct 2024.

A UK 2:1 honours degree or its international equivalent.

International qualifications

Check whether your international qualifications meet our general entry requirements:

• Entry requirements by country
• English language requirements

Regardless of your nationality or country of residence, you must demonstrate a level of English language competency at a level that will enable you to succeed in your studies.

English language tests

We accept the following English language qualifications at the grades specified:

• IELTS Academic: total 6.5 with at least 6.0 in each component. We do not accept IELTS One Skill Retake to meet our English language requirements.
• TOEFL-iBT (including Home Edition): total 92 with at least 20 in each component. We do not accept TOEFL MyBest Score to meet our English language requirements.
• C1 Advanced ( CAE ) / C2 Proficiency ( CPE ): total 176 with at least 169 in each component.
• Trinity ISE : ISE II with distinctions in all four components.
• PTE Academic: total 62 with at least 59 in each component.

Your English language qualification must be no more than three and a half years old from the start date of the programme you are applying to study, unless you are using IELTS , TOEFL, Trinity ISE or PTE , in which case it must be no more than two years old.

Degrees taught and assessed in English

We also accept an undergraduate or postgraduate degree that has been taught and assessed in English in a majority English speaking country, as defined by UK Visas and Immigration:

• UKVI list of majority English speaking countries

We also accept a degree that has been taught and assessed in English from a university on our list of approved universities in non-majority English speaking countries (non-MESC).

• Approved universities in non-MESC

If you are not a national of a majority English speaking country, then your degree must be no more than five years old* at the beginning of your programme of study. (*Revised 05 March 2024 to extend degree validity to five years.)

Find out more about our language requirements:

Fees and costs

Additional programme costs.

Most laboratories require a bench fee of up to £5,000 per year. This cost can be covered in Research Council studentships.

Living costs

You will be responsible for covering living costs for the duration of your studies.

Tuition fees

Scholarships and funding, featured funding.

• College of Medicine & Veterinary Medicine funding opportunities

UK government postgraduate loans

If you live in the UK, you may be able to apply for a postgraduate loan from one of the UK’s governments.

The type and amount of financial support you are eligible for will depend on your programme, the duration of your studies, and your residency status.

Programmes studied on a part-time intermittent basis are not eligible.

• UK government and other external funding

Other funding opportunities

Search for scholarships and funding opportunities:

• Search for funding

Further information

• Postgraduate Administrator, Kelly Douglas
• Phone: +44 (0)131 651 9500
• Contact: [email protected]
• Centre for Regenerative Medicine
• Institute for Regeneration and Repair
• The University of Edinburgh
• Little France
• Programme: Regenerative Medicine
• School: Edinburgh Medical School: Clinical Sciences
• College: Medicine & Veterinary Medicine

Select your programme and preferred start date to begin your application.

PhD Regenerative Medicine - 3 Years (Full-time)

Phd regenerative medicine - 6 years (part-time), application deadlines.

We encourage you to apply at least one month prior to entry so that we have enough time to process your application. If you are also applying for funding or will require a visa then we strongly recommend you apply as early as possible.

• How to apply

You must submit two references with your application.

Before making your application, you must make contact with a potential supervisor to discuss your research proposal. Further information on making a research degree application can be found on the College website:

• How to apply for a research degree

Find out more about the general application process for postgraduate programmes:

+1 (210) 458-6568

One UTSA Circle San Antonio, TX 78249

Regenerative Medicine

Regenerative medicine research program at utsa.

Learn more about the Regenerative Medicine Research Program at the University of Texas at San Antonio (UTSA), a part of our renowned Developmental & Regenerative Sciences (DRS) PhD program within the College of Sciences. Our mission is to delve into the intricacies of regenerative medicine and revolutionize the face of healthcare.

How does Regenerative Medicine Research Help

Our Regenerative Medicine Research Program provides students with a solid grounding in the rapidly evolving field of regenerative medicine, which focuses on repairing, replacing, or regenerating human cells, tissues, or organs to restore normal function. From stem cell therapy to tissue engineering, our curriculum covers a broad spectrum, equipping students to contribute significantly to this promising field.

UTSA stands at the forefront of innovative research in regenerative medicine. Under the mentorship of our distinguished faculty, students embark on pioneering research projects, employing the most advanced techniques and technologies. Our research spans a wide range of topics including stem cell applications, biomaterials, and tissue regeneration, constantly pushing the boundaries of biomedical sciences.

Benefits of our Program

Our Regenerative Medicine Research Program benefits from advanced research facilities, equipped with the latest in cell culture systems and biomaterial fabrication technologies. These resources, coupled with a vibrant academic environment, foster significant discoveries and offer students an enriching, hands-on learning experience in regenerative medicine research.

Graduates from our Regenerative Medicine Research Program find themselves well-prepared for a range of careers. Our alumni have gone on to make strides in academia, clinical research, biotech companies, and pharmaceutical industries, playing pivotal roles in the advancement of regenerative medicine. At UTSA, we’re not just training students; we’re shaping future leaders in regenerative healthcare.

Consider a PhD in Developmental and Regenerative Sciences at UTSA

Embarking on your journey with UTSA’s Regenerative Medicine Research Program means joining a dynamic community of researchers passionate about healing the human body from within. We invite you to be part of this groundbreaking journey, contributing to the advancements in regenerative medicine.

Take the first step toward a promising career in regenerative medicine. Apply to UTSA’s DRS PhD program today and be part of the future of healthcare.

• Lacy Barton
• Doug Frantz
• Brian Hermann
• Jenny Hsieh
• Lindsey Macpherson
• John McCarrey
• Christopher Navara
• Christopher Rathbone
• UTSA Institute of Regenerative Medicine
• UTSA Stem Cell Core
• U.S. Army Institute of Surgical Research
• U.S. Air Force 59th Medical Wing
• BioBridge Global/GenCure
• UTSA Brain Health Consortium
• UTSA Genomics Core
• UTSA Cell Analysis Core

Applications for Fall 2024 are Closed! Applications for Fall 2025 will open in August 2024. Application Deadline for Fall 2025 will be November 1, 2024 for consideration for fee waivers and/or additional financial incentives, or December 1, 2024 for all applications.

Information: (210) 458-6568

[email protected]

[email protected]

© 2024 UTSA DRS PhD Program

Designed by Azuro Digital

• Skip to Content
• Catalog Home
• Institution Home
• Graduate Catalog /
• Perelman School of Medicine /

Cell and Molecular Biology: Developmental, Stem Cell, and Regenerative Biology, PhD

Related programs.

• Cell and Molecular Biology: Cancer Biology, PhD
• Cell and Molecular Biology: Cell Biology, Physiology, and Metabolism, PhD
• Cell and Molecular Biology: Gene Therapy and Vaccines, PhD
• Cell and Molecular Biology: Genetics and Epigenetics, PhD
• Cell and Molecular Biology: Microbiology, Virology, and Parasitology, PhD

Cell and Molecular Biology

The Cell and Molecular Biology Graduate Group (CAMB) is an interdisciplinary graduate program, providing rigorous training in modern cell and molecular biology, preparing students for leadership careers in biomedical research. Within this integrated program are six discipline areas:  Cancer Biology ;  Cell Biology, Physiology, and Metabolism ;  Developmental, Stem Cell and Regenerative Biology ;  Gene Therapy and Vaccines ;  Genetics and Epigenetics ; and  Microbiology, Virology and Parasitology . Program faculty include more than 300 scientists representing 35 departments from the Perelman School of Medicine, the Schools of Arts and Sciences, Dental Medicine, and Veterinary Medicine, Children’s Hospital of Philadelphia, the Wistar Institute and Fox Chase Cancer Center. The research efforts of these scientists are diverse in their focus, experimental system, methodology, and represent the leading edge of basic and translational biomedical science.

Students from colleges and universities around the nation and the world are enrolled in the program, selecting one discipline area based on their scientific interests, yet have access to the full breadth of curricular and research opportunities provided by this large and diverse program. Our students participate in core courses in cell and molecular biology, specialized coursework in one or more discipline areas, and original hypothesis-driven thesis research. Upon completion of the PhD, they pursue successful research careers at top academic institutions, in the biotech and pharmaceutical industries, and in other biomedicine-related career paths.

For more information:  http://www.med.upenn.edu/camb/

Developmental, Stem Cell, and Regenerative Biology

Students within Developmental, Stem Cell, and Regenerative Biology address key questions in developmental biology, stem cell/niche interactions, and regenerative biology. The central focus that unites these areas is the compelling drive to understand how tissues are first formed, how they are maintained, and how they can be repaired. Students participate in interdisciplinary training in gametogenesis; embryonic and fetal development; nervous system development and its wiring; the genesis of tissues and organ systems as well as their homeostasis, metabolism and repair; with goal of understanding the basic biology of these processes, as well as their role in disease. Complementing these areas is work on natural and induced Embryonic Stem Cells to understand disease processes in vitro in order to develop cell replacement strategies for therapy. In conducting their research students utilize all tools of the modern genomic era and a wide variety of experimental model systems.

For more information: https://www.med.upenn.edu/camb/dsrb.shtml

View the University’s Academic Rules for PhD Programs .

Required Courses 

Or other statistics course with approval of the Graduate Group.

The degree and major requirements displayed are intended as a guide for students entering in the Fall of 2024 and later. Students should consult with their academic program regarding final certifications and requirements for graduation.

Sample Plan of Study

Print options.

Print this page.

The PDF will include all information unique to this page.

A PDF of the entire 2024-25 catalog.

A PDF of the 2024-25 Undergraduate catalog.

A PDF of the 2024-25 Graduate catalog.

The goal of the PhD program in Development, Stem Cells, and Regenerative Medicine is to train the next generation of investigators in the history and practice of developmental and stem cell biology. The ultimate aim is to understand how the genomes of animals are translated into complex morphological forms, and to apply this basic knowledge to the emerging field of regenerative medicine. Close and regular contact between participating faculty of different disciplines and students is expected to facilitate the application of multidisciplinary approaches toward regenerative medicine.

Development, Stem Cells, and Regenerative Medicine students are required to complete DSR 542    and at least 2 units from the following: DSR 610   , DSR 620   , INTD 504    or other courses approved by the faculty adviser. In the second and subsequent years, students are required to register in DSR 574    every fall and spring semester. In addition, students are required to complete at least 4 units of DSR 794a Doctoral Dissertation   ,  DSR 794b Doctoral Dissertation   .

PhD students must supplement course work by registering for DSR 790 Research    during the fall, spring and summer semesters as needed to complete the minimum 60 units required for the PhD program.

As part of the requirements for the PhD degree in Development, Stem Cells, and Regenerative Medicine, students must adhere to the unit/course requirements, guidance committee and dissertation committee guidelines and must complete the qualifying examination, annual research appraisal, and dissertation and oral defense as outlined in the sections following the descriptions of the PhD programs.

Cellular and Molecular Medicine, PhD

School of medicine.

The Graduate Training Program in Cellular and Molecular Medicine prepares scientists for laboratory research at the cellular and molecular level with a direct impact on the understanding, diagnosis, treatment, and prevention of human diseases. The Ph.D. graduates of the program obtain rigorous training in scientific research and develop a thorough knowledge of human biology and human diseases.

This program grew out of a need for graduate training at the interface between medicine and the traditional basic science disciplines. Rapid progress in cellular and molecular biology has strongly impacted clinical medicine, offering insights about the fundamental causes of many diseases. Translational research—often described as “bench-to-bedside” studies—accelerates the discovery of new treatments directed at the basic mechanisms of disorder and disease. Thus, the goal of this program is to train scientists who will make discoveries in the laboratory that can be applied expeditiously to the diagnosis, treatment, and prevention of disease. New technology allows scientists to identify genetic and molecular defects causing or predisposing to disease. The trainees in this program are working precisely at this interface between science and medicine to contribute to the long-term well-being of society.

Students will work in well-equipped laboratories of approximately 140 program faculty located throughout the medical school campus. These researchers are supported by many shared facilities including microscopy, molecular biology, and protein chemistry.

Financial Aid

The program is supported by a combination of monies from the Lucille P. Markey Charitable Trust and an NIH training grant. Each student is provided a stipend, health and dental insurance, and tuition throughout their years in the program. The program covers these benefits during the students’ first year; in subsequent years, the research advisor is responsible.

Admission Requirements

The mission of the CMM program is to recruit and train outstanding PhD candidates in translational research. We use a holistic approach in evaluating applicants, to ensure the best fit between our training program and trainees. Evidence of prior research experience is paramount in the admissions process, along with letters from research mentors. A bachelor’s degree from a qualified college or university is required. Applicants are expected to have taken the following courses: biology, inorganic chemistry, organic chemistry, physical chemistry, physics, and calculus. Cell biology and/or biochemistry is recommended. Passage of the TOEFL is required for all students whose undergraduate instruction was conducted in a language other than English. CMM does not require or review GRE scores in the admissions process.

CMM draws from the top of an extremely strong and deep pool of candidates.  Although we do not use score cut-offs, the average accepted student has a GPA of 3.71. Our class size varies between 20-24, and includes in addition to PhD candidates, trainees in dual MD/PhD, DVM/PhD programs and Clinical Fellows.  Yield on admissions offers is high, ranging from 45-69%, with an average of 55% of offers resulting in acceptance.

The Vivian Thomas Scholars Initiative (VTSI) is dedicated to nurturing, mentoring and connecting the exceptional diverse talent that exists at historically black colleges and universities (HBCUs) and other minority serving institutions. (MSIs) to STEM graduate education and future leadership in STEM careers.  The application for VTSI and the supplemental questions are found within the School of Medicine application for those interested in applying.

GEM (The National Consortium for Graduate Degrees for Minorities in Engineering and Science) award fellowships to eligible students who pursue graduate education in science or engineering.  For more information, please visit GEM Fellowship webpage .  Prospective fellows apply to GEM and the sponsoring institutions at the same time.  Potential candidates must indicate on the JHU application that they have received or are being considered for a GEM Fellowship.

Inquiries regarding admissions should be referred to:

Office of the Graduate Program in Cellular and Molecular Medicine 1830 E. Monument Street, Suite 2-103 Telephone: (410) 614-0391; (410) 614-3640

For questions not addressed on these pages, please email [email protected].

Program Requirements

Students must complete successfully the following courses:

Students are required to take four electives to further broaden their experience in cellular and molecular medicine during the duration of their studies.  Mandatory one elective out of the four required must be a Biostatistics course.  Rigor and Reproducibility in Research (3R's) principles are integrated throughout the program's coursework.  The Responsible Conduct of Research (RCR) ethics training taken in year one fulfills a graduation requirement.   An Ethics refresher course includes attending several Research Integrity Colloquium lectures each year.

Students are expected to perform research rotations in at least three different laboratories culminating with the selection of a thesis advisor to begin original research leading to their doctoral dissertation. All rotations must be performed in the laboratories of CMM faculty members.

Additionally, the program requires students to actively participate in the OPTIONS Career Curriculum , managed by the Professional Development and Career Office, that provides protected time for students to develop their career goals and prepare for their future. Through interactive workshops, students discover careers of interest, develop career-specific skills and build a professional network while connecting with fellow trainees with similar interests.

A University-mandated Doctor of Philosophy Board Oral Examination must be completed by the end of the second year of study. Annual thesis committee meetings are held until such time as the thesis committee believes the student is ready to write their doctoral dissertation. The dissertation is based on the student’s novel research; a public seminar of thesis work is a graduation requirement.

PhD Regenerative Medicine

Doctor of Philosophy - PhD

ECTS-Points

Learning format.

Blended learning

6 semesters

Admission requirements

Diploma or master's degree

Study location

Curriculum (PDF | 160 KB)

Regenerative medicine procedures and therapies represent a future field, even for diseases that were previously difficult or impossible to treat.

Univ.-Prof. Dr. Michael Bernhard Fischer

Phd coordinator.

Any questions?

We’re here to help.

Elisabeth Hintermayer

Administrative Assistant

Or contact us directly.

Benefit from our PhD program

The PhD program Regenerative Medicine combines excellent research in various areas of tissue and organ regeneration with an innovative curriculum. As "Early Stage Researchers", our students conduct research on topics such as inflammation and tissue damage and the resulting regenerative mechanisms.

The students are involved in externally funded research projects and are guided and supported on their scientific path by established researchers. Our aim is to optimally prepare students for research-based positions in both academia and industry.

Accreditation

In 2015, the Agency for Quality Assurance and Accreditation (AQ Austria) accredited the first two PhD programs at the University for Continuing Education Krems: “ Migration Studies ” and “Regenerative Medicine ”. This made the University for Continuing Education Krems one of the first public universities in Austria to have its PhD programs accredited according to international standards. In 2021, the PhD program " Technology, Innovation and Cohesive Societies " was also successfully accredited by AQ Austria. Most recently, the PhD program " Applied Evidence Synthesis in Health Research " was accredited by AQ-Austria in December 2023.

The innovative curriculum of the PhD program "Regenerative Medicine" combines compulsory modules with elective activities and work on the research project.

The program comprises 180 ECTS credits. The courses comprise 30 ECTS credits; the dissertation is worth 145 ECTS credits and the viva voce is worth 5 ECTS credits. 1 ECTS point corresponds to 25 hours of student work (in accordance with UG § 51 (26)).

Module 1: Methodology

Scientific Work and Good Scientific Practice

Ethics in Science

Scientific Presentations and Publications

Medical Biostatistics and Mathematics

Project Management

Study Design

Translation: From Theory to Clinical Application

Module 2: Biomedical Remedial Course

Cell Biology

Molecular Biology, Signal Transduction

Biochemistry

Module 3: Regenerative Sciences: Principles and Methods

Principles of Regenerative Medicine

Principles of Tissue Engineering

Biology of Stem Cells and Cell-Based Therapy

Inflammation and Sepsis

Inherited and Acquired Immunity

Flow Cytometry and Imaging (Microscopy, SEM, AFM, LSM etc.)

Cell Culture Models in Regenerative Medicine and Tissue Engineering

Module 4: Biomaterials

Biomaterials: Overview and Chemistry

Polymer Materials in Blood Purification

Blood/Material Interaction

Module 5: Advanced Regenerative Medicine and Tissue Engineering

Liver: Regeneration and Support

Degeneration and Regeneration of the Nervous System

Cartilage Regeneration

Applied Cell Therapy

Module 6: Journal Club and Degree Candidates Seminar

Journal Club

Doctoral Degree Candidates Seminar

Dissertation

The dissertation agreement – an agreement between the applicant and the first supervisor of the research work – is drawn up at the beginning of the degree program. It sets out the collaboration on the project as well as goals and plans. The supervisory team is also named.

All students are involved in collaborative research projects providing cross-disciplinary experience. Each student is assigned a primary and secondary supervisor with appropriate independent expertise in the project area. The progress is monitored by a PhD Committee that includes the two supervisors and at least one additional senior scientist, who meet to provide feedback on regular written and oral presentations.

The topic of the dissertation must be meaningfully related to the field of regenerative medicine, in particular to the following subject areas:

• Methods of organ support and extracorporeal blood purification
• Pathophysiology of sepsis and investigating inflammatory mechanisms
• Interaction of blood and/or tissue with biomaterials
• Regeneration of articular surfaces (cartilage transplants, therapy with growth factors, implanting mesenchymal stem cells)
• Immune regulatory mechanisms of mesenchymal stem cells
• Tissue and organ replacement/regeneration using stem cells
• Neuro-rehabilitation
• Geriatric rehabilitation and nursing science

Students & Projects

The students are involved in externally funded research projects.

Department for Biomedical Research

Core Faculty

Professor of Tissue and Organ Replacement

Univ.-Prof. Dr. Dr. Thomas Klestil

Professor for Clinical Research in Orthopedics and Traumatology

Univ.-Prof. Dr. Stefan Nehrer, MSc

Professor for Tissue Engineering

Univ.-Prof. Dr. Viktoria Weber

Professor for Medical Chemistry

ASSOCIATED MEMBERS OF PHD FACULTY

Prof. (fh) mag. dr. christoph wiesner.

Department of Science and Technology, Institute Biotechnology, IMC University of Applied Sciences Krems

Priv. Doz. Dr. Reinhard Klein

Priv. doz. prof. (fh) mag. dr. andreas eger.

Deputy Head of Institute / Institute Krems Bioanalytics, IMC University of Applied Sciences Krems

Extended Faculty

Univ.-Prof. Dr. Gerald Gartlehner, MPH

Professor for Evidence Based Medicine

Prof. Dott. Ing. Emanuele Gatti

Professor for Translation of Biomedical Innovations - Visiting Professor

Univ.-Prof. Dr. Christoph Pieh

Professor for Psychosomatic Medicine and Psychotherapy

Univ.-Prof. Dr. Michaela M. Pinter, MAS

Professor for Neurorehabilitation Research

Univ.-Prof. PD Dr. Thore Zantop

Professor for Sports and Exercise Medicine

Here you can find more information about the PhD program.

Application

Admission to the PhD program " Regenerative Medicine " follows a two-stage process:

• Announcement of third-party-funded PhD positions
• Selection procedure by the PhD Commission

PhD students are generally employed on the basis of research projects with third-party funding (FWF reference rates). The PhD Commission selects students on the basis of their application documents and the presentation of their dissertation project.

Required application documents are

• Curriculum Vitae
• Proof of identity (passport, identity card)
• Final degree certificate
• Degree, diploma or master's degree certificate
• Summary of research idea
• Letter of motivation
• Recommendation letters and references

Students will be admitted to the program once all requirements have been met.

• #Regenerative Medicine
• #Biomedicine

Study & Research

• Studies Overview
• Studying parallel to employment
• Accessible studying
• Application & Admission
• Service Center for Students
• Research Highlights
• Research database
• Intellectual Capital Report
• Research Report
• Tech Support
• Press and Media
• Mitteilungsblätter (in German)
• Newsletter (in German)
• COVID-19 informations
• Library & University Archives
• About Campus Krems
• University Sports Institute Krems
• Campus Culture

Dr.-Karl-Dorrek-Straße 30 3500 Krems

[email protected] +43 2732 893 6000

• Imprint & Disclosure
• Privacy Policy
• Official Signature

University for Continuing Education Krems

Doctor of Medicine Program

• Social and Public Health Responsibility
• Collaboration and Communication
• Respect/ Ethical Behavior/ Professionalism
• Fiscal Responsibility and Accountability

Our Mission and Vision

The University of Maryland School of Medicine  provides an inclusive learning environment and that develops leaders in medicine who strive to improve the health and well-being of patients and communities through high-quality and equitable patient care, research, education, and engagement in a culturally relevant and socially responsible manner.

Our Vision is to create an environment where a diverse student body has the opportunity and support to achieve at the highest levels in all areas and missions of careers in medicine.

Undergraduate Medical Education Offices

The four Undergraduate Medical Education Offices work collaboratively to successfully steward our medical students from application to graduation.

Combined Degrees

MD/PhD MD/PhD Our mission is to train a diverse and creative cadre of physician- scientists who will become leaders in their chosen fields of research, develop new knowledge and translate it to enhance clinical practice. Medical Scientist Training Program (MSTP)

MD/Masters The MD/Masters Programs at the UMSOM provide medical students with advanced training in specific areas to complement and enhance their medical training and maximize opportunities after graduation.

Doctor of Medicine Program Resources

Undergraduate Medical Education Leadership

Donna Parker, MD Senior Associate Dean for Undergraduate Medical Education, Professor of Medicine 410-706-7476 [email protected]

Paul Moore, BS Instructional Support Services: Director HSF-I 316 [email protected]

Kevin Brown, MS Assistant Dean for Undergraduate Medical Education Operations [email protected] 410-706-7668

Doug Clarke, MEd Associate Director: Quality, Compliance and Accreditation HSF-I 316 [email protected]

John T. Milliken Department of Medicine

Ying Maggie Chen Receives Grant from WashU Center of Regenerative Medicine

The  Center of Regenerative Medicine  (CRM) at Washington University has awarded  Ying Maggie Chen , MD, PhD, a one-year grant for her proposal entitled “Personalized kidney organoid modeling to develop novel treatment for uromodulin-associated chronic kidney disease.”

share this!

May 30, 2024

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

Ancient medicine blends with modern-day research in new tissue regeneration method

by Bailey Noah, Texas A&M University College of Engineering

For centuries, civilizations have used naturally occurring, inorganic materials for their perceived healing properties. Egyptians thought green copper ore helped eye inflammation, the Chinese used cinnabar for heartburn, and Native Americans used clay to reduce soreness and inflammation.

Flash forward to today, and researchers at Texas A&M University are still discovering ways that inorganic materials can be used for healing.

In two recently published articles, Dr. Akhilesh Gaharwar, a Tim and Amy Leach Endowed Professor in the Department of Biomedical Engineering, and Dr. Irtisha Singh, assistant professor in the Department of Cell Biology and Genetics, uncovered new ways that inorganic materials can aid tissue repair and regeneration.

The first article , published in Acta Biomaterialia , explains that cellular pathways for bone and cartilage formation can be activated in stem cells using inorganic ions. The second article , published in Advanced Science , explores the usage of mineral-based nanomaterials, specifically 2D nanosilicates, to aid musculoskeletal regeneration.

"These investigations apply cutting-edge, high-throughput molecular methods to clarify how inorganic biomaterials affect stem cell behavior and tissue regenerative processes," Singh said.

The ability to induce natural bone formation holds promise for improvements in treatment outcomes, patient recovery times and the reduced need for invasive procedures and long-term medication.

"Enhancing bone density and formation in patients with osteoporosis, for example, can help mitigate the risks of fractures, lead to stronger bones, improve quality of life and reduce health care costs," Gaharwar said. "These insights open up exciting prospects for developing next-generation biomaterials that could provide a more natural and sustainable approach to healing."

Gaharwar said the newfound approach differs from current regeneration methods that rely on organic or biologically derived molecules and provides tailored solutions for complex medical issues.

"One of the most significant findings from our research is the ability of these nanosilicates to stabilize stem cells in a state conducive to skeletal tissue regeneration," he said. "This is crucial for promoting bone growth in a controlled and sustained manner, which is a major challenge in current regenerative therapies."

Gaharwar plans to continue developing biomaterials for clinical applications. He will use inorganic biomaterials in conjunction with 3D bioprinting techniques to design custom bone implants for reconstructive injuries.

"In reconstructive surgery , particularly for craniofacial defects, induced bone growth is crucial for restoring both function and appearance, vital for essential functions like chewing, breathing and speaking," he said. "Inducing bone formation has several critical applications in orthopedics and dentistry."

Former biomedical engineering graduate student, Dr. Anna Kersey '23, was the lead author for the article published in Acta Biomaterialia and biomedical engineering graduate student Aparna Murali was the lead author for the follow-up article published in Advanced Science .

"This approach not only bridges ancient practices with modern scientific methods but also minimizes the use of protein therapeutics, which carry risks of inducing abnormal tissue growth and cancerous formations," Gaharwar said.

"Collectively, these findings elucidate the potential of inorganic biomaterials to act as powerful mediators in tissue engineering and regenerative strategies, marking a significant step forward in the field."

Aparna Murali et al, Inorganic Biomaterials Shape the Transcriptome Profile to Induce Endochondral Differentiation, Advanced Science (2024). DOI: 10.1002/advs.202402468

Journal information: Advanced Science , Acta Biomaterialia

Provided by Texas A&M University College of Engineering

Explore further

Feedback to editors

How worms shaped Earth's biodiversity explosion

3 hours ago

Meet Neo Px: the super plant that attacks air pollution

A Chinese spacecraft lands on the moon's far side to collect rocks in growing space rivalry with US

Saturday Citations: The sound of music, sneaky birds, better training for LLMs. Plus: Diversity improves research

Jun 1, 2024

Study investigates a massive 'spider' pulsar

Greener, more effective termite control: Natural compound attracts wood eaters

Shear genius: Researchers find way to scale up wonder material, which could do wonders for the Earth

New vestiges of the first life on Earth discovered in Saudi Arabia

May 31, 2024

Mussels downstream of wastewater treatment plant contain radium, study reports

A new way to see viruses in action: Super-resolution microscopy provides a nano-scale look

Relevant physicsforums posts, a dna animation.

May 29, 2024

Probability, genetic disorder related

May 28, 2024

Looking For Today's DNA Knowledge

May 27, 2024

Covid Vaccines Reducing Infections

Human sperm, egg cells mass-generated using ips, and now, here comes covid-19 version ba.2, ba.4, ba.5,....

May 25, 2024

More from Biology and Medical

Related Stories

Engineering researchers develop porous nanoparticles for regenerative medicine

Mar 30, 2022

Scientists develop new multicellular scaffold strategy for treating tendon-bone injuries

Mar 14, 2024

Multiple biomaterials for immediate implant placement tissue repair: Current status and future perspectives

Mar 29, 2024

Minerals can be key to healing damaged tissue

May 9, 2022

Researchers develop new therapeutic approach to treating osteoarthritis

Feb 19, 2019

Team engineers 3-D-functional bone tissues

May 19, 2020

Recommended for you

This tiny fern has the largest genome of any organism on Earth

Researchers discover 'Trojan Horse' virus hiding in human parasite

The world famous Roman Baths could help scientists counter the challenge of antibiotic resistance

Stem cell study sheds new light on how the human embryo forms

The world's most powerful anti-fungal chemistries cause fungal pathogens to self-destruct

Let us know if there is a problem with our content.

Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form . For general feedback, use the public comments section below (please adhere to guidelines ).

Please select the most appropriate category to facilitate processing of your request

Thank you for taking time to provide your feedback to the editors.

Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

E-mail the story

Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Phys.org in any form.

Newsletter sign up

Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we'll never share your details to third parties.

More information Privacy policy

Donate and enjoy an ad-free experience

We keep our content available to everyone. Consider supporting Science X's mission by getting a premium account.

E-mail newsletter

EDI Spotlight: Michael Boyce, PhD

After first joining Duke’s faculty in 2012, it didn’t take Michael Boyce, PhD, long to get involved in equity, diversity, and inclusion work — not only within his department but also on the national scene. In this month’s EDI Spotlight, Boyce, an associate professor, shares how his passion for the work led him to be actively involved with the Department of Biochemistry’s EDI committee since its inception. Additionally, he has become a leader of a national program that seeks to transition scientists from diverse backgrounds into tenure-track research faculty jobs across the country. He also tells us about his love of travel, including a few upcoming international trips with his partner.

You are an associate professor of biochemistry whose research focuses on mammalian cell signaling through protein glycosylation. What does a typical day for you look like?

One thing I like about my job is that every day is different. Of course, research and the people in my lab are a major focus, so I’m often meeting with students, postdocs, and staff, individually or in groups, to discuss data, plan strategy, troubleshoot, write grants or papers, etc. I also enjoy teaching (particularly small-group seminars for PhD students) and service, much of which is focused on graduate education and equity, diversity, and inclusion (EDI) in my case. Another thing I value about my job is that it entails both work within my subject matter (e.g., with colleagues in the Biochemistry Department or globally in the glycobiology field) and interactions with colleagues in other fields from around Duke and through national organizations, such as the American Society for Cell Biology (ASCB).

Aside from your responsibilities as a researcher, you also have been actively involved in equity, diversity, and inclusion initiatives within the Department of Biochemistry. What are some of those initiatives? How and why did you first become involved in EDI in your department?

I’ve been involved in EDI efforts in Biochemistry since 2013, soon after I began at Duke in October 2012. A lot of credit for this goes to Dick Brennan , our department’s longtime chair. He created an EDI committee in the department in 2013, which I have continuously served on and co-chaired over the years. Dick has steadfastly supported and valued our committee’s contributions to the department – not in a merely performative way, but by committing his actions and department resources (money) to empower our activities.

True story: I visited another university a couple months ago to give an invited seminar on my research. In a one-on-one meeting with a new junior faculty member there, he saw on my CV that I had been on the EDI committee for Duke Biochemistry since 2013, and he was impressed and wondered if our committee was the first in the nation (!). I’m not sure we quite hold that record, but I think this reaction speaks volumes about the longstanding commitment that Dick and many students, postdocs, staff and faculty members have contributed to our department’s committee over the years.

You currently serve as co-director of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program, which is designed to facilitate the transition of promising postdoctoral researchers from diverse backgrounds. Tell us a little about the MOSAIC program and what motivated you to get involved.

I’m so fortunate to be involved in MOSAIC, which I think is a tremendously valuable and impactful program. The mission of the NIH MOSAIC program is to increase the diversity of tenure-track biomedical faculty at research-intensive universities nationwide. MOSAIC aims to achieve this goal through two related mechanisms: 1) K99/R00 fellowships that support the postdoc-to-faculty transition of extremely talented scholars who increase diversity and inclusions through their lived experience and/or their service activities, and 2) UE5 awards to scientific societies, which create cohort-based programs to provide skills development, professional networking, and other support to groups of MOSAIC scholars. I have co-directed the ASCB UE5-funded MOSAIC program since its inception, and I work closely with our 50+ rock-star K99/R00 scholars, who continually impress me with their accomplishments.

What impact has the MOSAIC program had since it began in 2020? How has it enhanced diversity within the academic biomedical research workforce?

As the National Institute of General Medical Sciences (NIGMS) and NIH in general have wisely recognized, diversifying the biomedical workforce is good for the United States because it helps us maximize the talent flowing into our scientific enterprise, and it better serves the population of our country, providing intellectual and professional opportunities for as many people as possible.

Already, dozens of our MOSAIC scholars in the ASCB program have taken outstanding faculty positions at great institutions around the country, and many more are in the pipeline. This is also true for the scholars in the other UE5 organizations, beyond ASCB. In other words, MOSAIC has helped to place and support scores of scholars of highly diverse backgrounds in influential, tenure-track faculty positions across the US. The impact of the program will therefore ramify for decades, as these scholars do great science and teach and train tens of thousands of students, postdocs, and other learners.

Closer to home, MOSAIC also has strong ties to Duke through several scholars, such as Duke Neurobiology alum Erica Rodriguez, former Duke postdoc and current NCSU faculty member Ian Williamson, and current Duke faculty member Asiya Gusa . Suzanne Barbour (Dean of the Graduate School) and Gustavo Silva (Associate Professor of Biology) are also involved in other MOSAIC UE5 programs. I hope Duke will hire more MOSAIC scholars as faculty in the future (looking at you, administrator colleagues!) and I hope anyone interested in learning more will check out the NIGMS MOSAIC page and the ASCB MOSAIC Program website.

What passions or hobbies do you have outside of work?

I try to prioritize work-life balance, but I have to admit that my hobbies are maybe a little bit pedestrian! I always make time for exercise (so important for both mental and physical health), and I love cooking, eating, and traveling with my partner, Solomon. This year, we’re fortunate to have trips to Mexico and several countries in South America.

• Education Home
• Medical Education Technology Support
• Graduate Medical Education
• Medical Scientist Training Program
• Public Health Sciences Program
• Continuing Medical Education
• Clinical Performance Education Center
• Center for Excellence in Education
• Research Home
• Biochemistry & Molecular Genetics
• Biomedical Engineering
• Cell Biology
• Microbiology, Immunology, & Cancer Biology (MIC)
• Molecular Physiology & Biological Physics
• Neuroscience
• Pharmacology
• Public Health Sciences
• Office for Research
• Clinical Research
• Clinical Trials Office
• Funding Opportunities
• Grants & Contracts
• Research Faculty Directory
• Cancer Center
• Cardiovascular Research Center
• Carter Immunology Center
• Center for Behavioral Health & Technology
• Center for Brain Immunology & Glia
• Center for Diabetes Technology
• Center for Immunity, Inflammation & Regenerative Medicine
• Center for Public Health Genomics
• Center for Membrane & Cell Physiology
• Center for Research in Reproduction
• Myles H. Thaler Center for AIDS & Human Retrovirus Research
• Child Health Research Center (Pediatrics)
• Division of Perceptual Studies
• Research News: The Making of Medicine
• Core Facilities
• Virginia Research Resources Consortium
• Center for Advanced Vision Science
• Charles O. Strickler Transplant Center
• Keck Center for Cellular Imaging
• Institute of Law, Psychiatry & Public Policy
• Translational Health Research Institute of Virginia
• Clinical Home
• Anesthesiology
• Dermatology
• Emergency Medicine
• Family Medicine
• Neurosurgery
• Obstetrics & Gynecology
• Ophthalmology
• Orthopaedic Surgery
• Otolaryngology
• Physical Medicine & Rehabilitation
• Plastic Surgery, Maxillofacial, & Oral Health
• Psychiatry & Neurobehavioral Sciences
• Radiation Oncology
• Radiology & Medical Imaging
• UVA Health: Patient Care
• Diversity Home
• Diversity Overview
• Student Resources
• GME Trainee Resources
• Faculty Resources
• Community Resources

Anna Cliffe, PhD, Awarded $2.7 Million to Study How ATRX Protein Protects Against Herpes Simplex Virus

May 29, 2024 by [email protected]

Anna Cliffe, PhD

Anna Cliffe, PhD, an associate professor in the Department of Microbiology, Immunology, and Cancer Biology, was awarded a $2.7 million R01 grant from the National Institutes of Health for a project titled “The role of ATRX in both promoting the establishment of HSV latency and restricting reactivation.”

The Cliffe lab studies mechanisms of Herpes Simplex Virus (HSV) latent infection and reactivation in neurons. More than 60% of the U.S. population is infected with the virus, which can cause a range of disease outcomes, including oral and genital lesions, keratitis, and encephalitis, and potentially contribute to the development of Alzheimer’s disease. The virus persists for life as a latent infection of neurons and can periodically reactivate in response to a variety of stimuli to cause disease.

The new R01 grant will aim to determine the mechanistic role of a host protein ATRX (Alpha thalassemia/mental retardation syndrome X-linked) in promoting entry into latent infection in neurons and preventing reactivation. ATRX is an abundant neuronal protein that protects neurons from aberrant gene expression during stress. Abigail Whitford, a graduate student in the Cliffe lab, has found that ATRX also protects neurons from HSV reactivation. A subpopulation of latent viral genomes in neurons associate with ATRX, and these genomes are less likely to reactivate. The project aims to understand how ATRX silences HSV gene expression in neurons and determine whether targeting ATRX is a potential therapeutic strategy to limit HSV reactivation in response to a variety of stimuli. An alternative to be tested is that latent viral genomes associate with distinct proteins as an evolutionary “bet-hedging” approach, enabling different genomes to reactivate in response to different stimuli. Mutations in ATRX are associated with neurodevelopmental disease in addition to glioma. Therefore, this project will inform on the mechanisms of HSV latency and shed light on ATRX function in neurons, potentially informing the study of other diseases.

Seed funds for this project were provided by the Owens Family Foundation. Abigail Whitford was previously supported by the UVA Infectious Disease T32 Training grant with principal investigators Alison Criss, PhD, and William Petri, MD, PhD, and a UVA Wagner Fellowship. David Kashatus, PhD, is a collaborator on this project.

Filed Under: Research

• Submit News/Event
• Subscribe to News
• Call for Nominations
• Dean's Message
• Diversity, Equity & Inclusion
• Honors & Awards
• Media Highlights
• Philanthropy

COVID-19: Vaccine Program | Testing |  Visitor Guidelines | Information for Employees MONKEYPOX: UConn Health is NOT currently offering the monkeypox vaccine. Please visit the CT DPH website for more information or contact your health provider directly. -->

School of Medicine

Graduate Medical Education

UConn School of Medicine Graduate Medical Education is committed to supporting the well-being of all our residents and fellows during their training. For a full list of resources offered through UConn Health, the Capital Area Health Consortium and the broader community, please visit the Graduate Medical Education Office  Well-Being website .

The UConn Sleep Medicine Fellowship Program has also implemented initiatives to enhance well-being and successful work/life balance among its faculty and fellows. As burnout has risen among healthcare providers nationally, we have aimed to create an atmosphere of collegiality, support, and professional growth for the fellows and faculty in our program.

TIME OFF FOR PERSONAL AND MEDICAL APPOINTMENTS

As a fellow, your physical and mental health is a priority to both UConn Health and the Sleep Medicine Fellowship Program. You'll have access to several resources to promote well-being, as well as time off clinical duties to attend appointments.

Elective Freedom

The Sleep Medicine fellow has relative freedom in how they choose to spend their substantial elective time and are able to adjust and modify schedules to best fit their interests and priorities, with the guidance of the fellowship program director and associate program director. We have developed a well-being plan which includes routinely checking in with each fellow.

Work and train directly WITH PROGRAM DIRECTOR

Our fellow trains directly with the program director in the adult clinic setting, the associate program director in the pediatric setting, as well as in sleep study interpretation. In addition, our dedicated teaching faculty are available to provide comprehensive educational advice and personal support.

ORGANIZED ACTIVITIES

• Annual Holiday Dinner

OTHER BENEFITS

• Free confidential counseling services and free psychiatric care for fellows in need
• Free parking at all training sites
• $2,000 annual travel stipend to attend educational conferences
• $1,000 stipend for qualified educational purchases
• Four weeks of paid vacation annually
• Outstanding insurance offerings
• CAHC employee discounts

About the Stanford Interdisciplinary PhD Program in Stem Cell and Regenerative Medicine

In 2011, Stanford University’s Interdisciplinary PhD Program in Stem Cell Biology and Regenerative Medicine (SCBRM) was the first new School of Medicine doctoral program to be approved by the Faculty Senate in more than 20 years. When chartered, the SCBRM Program also became the first graduate program in the world to offer specialized training at the intersection of basic and clinical science with specific emphasis on Stem Cell Biology and Regenerative Medicine. 

From basic to translational research . Thesis research by SCBRM Ph.D. students spans the gamut from basic research to translational research, all with implications for stem cell biology and its applications to regenerative medicine. Our program is embracing the spirit of creativity and based on the principle that a detailed understanding of fundamental molecular and cellular mechanisms is the foundation for innovation in clinical translation. We also believe that basic scientists themselves are best at translating their own discoveries. Along those lines, our Ph.D. students explore fundamental mechanisms of how cells signal to one another, such as communication between stem cells and their niches, how the identities of various cell-types are established during development, from stem cells or by induced cellular reprogramming, and how aging occurs in animal models. They also develop efficient therapeutically relevant genome editing strategies, develop next generation, stem cell-based therapies, explore the inherited basis of complex human diseases by introducing genetic variants into cultured stem cells, and directed the  in vitro  differentiation of stem cells into therapeutically-valuable types of cells. SCBRM Ph.D. students are exposed to, and often exploit, the latest cutting-edge technologies including genome editing, single-cell transcriptional and chromatin analyses, cutting-edge microscopy and advanced stem cell culture systems. It is an exciting time to be immersed in stem cell research and regenerative medicine. 

A diversity of scientific disciplines . The inherent nature of stem cell biology is its interdisciplinarity. Depending on their choice of thesis project and faculty mentor, SCBRM Ph.D. students have drawn upon a number of disciplines—including biochemistry, cell biology, developmental biology, neuroscience, genomics, materials science, bioengineering, and computer science—in order to accomplish their work. SCBRM Ph.D. students thus benefit from the rich diversity of disciplines represented on the highly interdisciplinary Stanford University campus. There are many faculty members on the larger Stanford campus whose groundbreaking advances provide the biological breakthroughs, technologies, and tools for the next generation of treatments and cures.  

Education and research . Our doctoral program provides exceptional didactic education and research experience in the basic sciences underlying stem cell biology. In addition, program participants will receive specialized training in the development and clinical application of discoveries in the basic sciences to achieve regenerative therapies. Our graduates thus will be uniquely positioned to develop successful translational careers in Stem Cell Biology and Regenerative Medicine, and will emerge prepared to deliver on their passion to improve the human condition. Indeed, former SCBRM Ph.D. students have gone on to assume positions in academic research, medicine, biotechnology companies, finance, and other industries. 

Community . The Interdisciplinary PhD Program in Stem Cell Biology and Regenerative Medicine (SCBRM) is a Home Program that is part of the broader Stanford Biosciences “umbrella” program ( https://biosciences.stanford.edu/ ), with two important ramifications. First, our commitment is to fully fund all SCBRM Program students throughout graduate school. Students are encouraged to submit applications for independent funding through NIH, NSF, and other organizations. Second, once admitted to the SCBRM Program, PhD students can ask to rotate with any faculty member in the Stanford Institute for Stem Cell Biology and Regenerative Medicine ( https://med.stanford.edu/stemcell.html ), or more broadly, any faculty member at Stanford University. If the faculty member agrees, the student can select a dissertation co-mentor or primary advisor from any department or graduate program.  

Learn about the many ways to support the institute for Stem Cell Biology and Regenerative Medicine

Health for all, Hunger for none

• English (EN)
• Bayer in the U.S.
• Diversity, Equity & Inclusion
• Sustainability
• Political Disclosures by State
• Consumer Product Safety
• Resources Hub
• U.S. Crop Science
• Ag Innovation
• Collaboration
• In the Community
• Research & Resources
• Take Care, Now: Improving Access to Health and Nutrition
• America’s Famers Grow Communities
• Cultivating Ag Leaders
• Global Crop Science Division
• Consumer Health
• Focus Areas
• Pharmaceutical Brands
• Patient Assistance
• U.S. Transparency
• Global Pharmaceuticals Division
• Improving Access to Health and Nutrition
• Cultivating STEM Leaders
• Luke Bryan Farm Tour
• BioPartnering Solutions
• News & Stories
• Bayer in Lubbock Texas
• Community  
• Bayer in Puerto Rico
• Grants & Scholarships - Bayer Fund
• Corporate Giving
• Bayer Patient Assistance Foundation
• Media Contacts
• Global Media Hub
• Essure Information
• Working at Bayer
• Development & Teamwork
• Meet Our Employees
• Reputation & Impact
• Students and New Graduates
• Experienced Professionals
• Military Professionals & Protected Veterans
• Persons with Disabilities
• Temporary Employment
• Innovation & Solutions
• Onboarding Program
• Work Life Programs
• #Bayer360 Virtual Reality Career Experience
• Talent Community

BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel

• Regenerative Medicine Advanced Therapy (RMAT) designation follows phase I clinical trial results demonstrating that bemdaneprocel is well tolerated with no major safety issues through 18 months
• Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease

Berlin, Germany and Cambridge, MA, USA, May 30, 2024 – Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today that BlueRock’s investigational cell therapy bemdaneprocel for the treatment of Parkinson’s disease has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA).

Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating Parkinson’s disease. Phase I clinical trial data announced in March demonstrated that at 18 months it was well tolerated with no major safety issues. In addition, an observed increase in the F-DOPA PET imaging signal after stopping immune suppression therapy at 12 months, as defined in the study’s protocol, demonstrates that the transplanted cells survive and engraft in the brain.

Managed by the FDA’s Center for Biologics, Evaluation and Research (CBER), the RMAT program is dedicated to investigational regenerative medicines, including cell therapies, intended to treat, modify, reverse, or cure serious diseases. Investigational therapies that receive RMAT designation are eligible to receive expedited development review and development planning guidance from senior CBER managers. RMAT also creates a pathway for early discussions about potential surrogate endpoints and ways to support accelerated approval and satisfy post approval requirements.

“The RMAT designation for bemdaneprocel underscores the potential of this candidate to fundamentally change the way we think about Parkinson’s disease care,” said Christian Rommel, PhD, Head of Research and Development at Bayer’s Pharmaceuticals Division. “We are driven by our commitment to deliver breakthrough innovation for patients and are proud and excited to see bemdaneprocel continuing to clear hurdles in the development process.”

About bemdaneprocel (BRT-DA01) and the Phase I Trial Bemdaneprocel (BRT-DA01) is an investigational cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease. These dopaminergic neuron precursors are derived from pluripotent stem cells that are human embryonic stem cells. In a surgical procedure, these neuron precursors are implanted into the brain of a person with Parkinson’s disease. When transplanted, they have the potential to reform neural networks that have been severely affected by Parkinson’s and restore motor and non-motor function to patients. Bemdaneprocel has not been approved for treatment of any disease or medical condition by any health authority.

This The phase I study is a multi-center, multi-site, open-label, non-randomized, non-controlled study. Twelve (12) subjects diagnosed with Parkinson’s disease received surgical transplantation of 1 of 2 different dose levels of bemdaneprocel cells to the post-commissural putamen bilaterally, and administration of a 1-year immunosuppression regimen. Cohort A (5 subjects) received a dose of 0.9 million cells per putamen. Cohort B (7 subjects) received 2.7 million cells per putamen. Safety and tolerability were assessed at 1 year as the primary endpoint, along with evidence of cell survival and motor effects. The feasibility of transplantation was also assessed. Assessments were repeated at 18 months. All assessments will continue over 2 years.

The transplant surgeries were performed by Dr. Viviane Tabar, MD, Chair of the Department of Neurosurgery at Memorial Sloan Kettering (MSK) Cancer Center and Dr. Andres Lozano, M.D., Ph.D., F.R.C.S.C., F.R.S.C., F.C.A.H.S., Neurosurgeon and Senior Scientist, Krembil Brain Institute, University Health Network (UHN), Alan & Susan Hudson Cornerstone Chair in Neurosurgery, Toronto Western Hospital, University Health Network and Chairman of the Division of Neurosurgery at the University of Toronto (UoT). Participants were followed at clinical sites by Dr. Harini Sarva, M.D. at Weill Cornell Medicine, Dr. Claire Henchcliffe, M.D., D.Phil., F.A.A.N., F.A.N.A. at the University of California, Irvine, and Dr. Alfonso Fasano, M.D., PhD., Chair in Neuromodulation and Multi-Disciplinary Care at the University Health Network (UHN) and UoT.  

Disclosure:  

Memorial Sloan Kettering (MSK): Dr. Tabar has financial interests related to BlueRock. MSK has institutional financial interests related to BlueRock. Note the foregoing institutional disclosure language is included because the referenced study relates to MSK technology licensed to BlueRock. University Health Network (UHN): UHN has institutional financial interests related to BlueRock.

More information about the Phase I trial is available at clinicaltrials.gov ( NCT04802733 ).

About Parkinson’s disease Parkinson’s disease is a progressive neurodegenerative disorder caused by the death of nerve cells in the brain, leading to decreased dopamine levels. At diagnosis, it is estimated that patients have already lost 50-80% of their dopaminergic neurons. The loss of these neurons leads to a progressive loss of motor function and symptoms such as tremors, muscle rigidity, and slowness of movement. Even with medication, the symptoms of Parkinson’s disease can fluctuate during the course of the day. According to the Parkinson’s Foundation, more than 10 million people worldwide suffer from Parkinson’s disease, with approximately one million living in the United States. There is no cure, and the effectiveness of current treatments decreases over time.

About BlueRock Therapeutics LP BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. We are harnessing the power of cell therapy to create a pipeline of new medicines for patients suffering from neurological, cardiovascular, immunological, and ophthalmic diseases. Our lead clinical program, bemdaneprocel, (BRT-DA01) is in Phase I clinical trials for Parkinson’s disease. We were founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed Cell & Gene Therapy Platform. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves. For more information, visit www.bluerocktx.com

About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. 

BlueRock Therapeutics Media Contact:  Jeff Lockwood, phone +1 617.510.6997 Email: [email protected]

Bayer Media Contact: Dr. Nuria Aiguabella Font, phone +49 1732329691 Email: [email protected]

Bayer U.S. Media Contact: Carolyn Nagle, phone +1 2014190337 Email: [email protected]

Contact for investor inquiries: Bayer Investor Relations Team, phone +49 214 30-72704 Email: [email protected]  www.bayer.com/en/investors/ir-team

Find more information at www.bluerocktx.com Follow us on LinkedIn/bluerocktx

Find more information at https://pharma.bayer.com/

Forward-Looking Statements  This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 

• Skip to Content
• Catalog Home

Instructional Coaching, Graduate/Professional Certificate

The University of Wisconsin–Madison offers an online Instructional Coaching Certificate embedded within the Master of Science for Professional Educators (MSPE) Program. This program helps current and aspiring instructional coaches engage in reflective dialogue, use student evidence, and build meaningful relationships to enhance their coaching practices. The certificate is only available to those enrolled in the MSPE Program. 

The Certificate in Instructional Coaching is open to students in the Masters in Educational Psychology: Named Option in Professional Educators program. Contact the program director for application information ( [email protected] ).

In addition to the steps outlined above, all Graduate School students must utilize the Graduate Student Portal in MyUW to add, change, or discontinue any graduate/professional certificate. For the final step required to apply to this certificate, log in to MyUW, click on Graduate Student Portal, and then click on Add/Change Programs. Select the information for the graduate/professional certificate for which you are applying.

• Requirements

 Complete the following coursework for a total of 9 credits.

• Learning Outcomes
• Examine the philosophy and core practices of Instructional Coaching
• Plan and facilitate coaching cycles in a way that establishes a culture of collective efficacy in a school/district/organization.
• Analyze data (evidence) gathered from different assessments to better understand how data can be used as an effective instructional coaching tool.
• Articulate and refine instructional coaching beliefs by drawing on research and examining own practice.

Contact Information

Educational Psychology School of Education edpsych.education.wisc.edu

Lisa Hebgen, Director, Master of Science for Professional Educators [email protected] 608-574-0355 863E Educational Sciences Building 1025 W. Johnson St., Madison, WI 53706

Graduate School grad.wisc.edu

• /​api/​
• /​pdf/​
• Explore Graduate Opportunities
• Explore UW-​Madison's Undergraduate Opportunities
• Accounting and Information Systems
• African American Studies
• African Cultural Studies
• Agricultural and Applied Economics
• Agricultural and Life Sciences -​ College-​Wide
• Animal and Dairy Sciences
• Anthropology
• Art History
• Asian Languages and Cultures
• Atmospheric and Oceanic Sciences
• Bacteriology
• Biochemistry
• Biological Systems Engineering
• Biomedical Engineering
• Biostatistics and Medical Informatics
• Business -​ School-​Wide
• Cell and Regenerative Biology
• Chemical and Biological Engineering
• Chicana/​o and Latina/​o Studies
• Civil and Environmental Engineering
• Civil Society &​ Community Studies
• Classical and Ancient Near Eastern Studies
• Communication Arts
• Communication Sciences and Disorders
• Community and Environmental Sociology
• Computer Sciences
• Counseling Psychology
• Curriculum and Instruction
• Educational Leadership and Policy Analysis
• Educational Policy Studies
• Educational Psychology, Doctoral Minor
• Educational Psychology, MS
• Educational Psychology, PhD
• Instructional Coaching, Graduate/​Professional Certificate
• Prevention and Intervention Science, Doctoral Minor
• Prevention and Intervention Science, Graduate/​Professional Certificate
• School Psychology, EdS
• School Psychology, MS
• School Psychology, PhD
• Electrical and Computer Engineering
• Engineering -​ College-​Wide
• Food Science
• Forest and Wildlife Ecology
• French and Italian
• Gaylord Nelson Institute for Environmental Studies
• Gender and Women's Studies
• German, Nordic, and Slavic
• Graduate -​ School-​Wide
• Human Ecology -​ School-​Wide
• Industrial and Systems Engineering
• Information School
• Institute for Clinical and Translational Research
• Institute for Regional and International Studies
• Integrative Biology
• Journalism and Mass Communication
• Kinesiology
• La Follette School of Public Affairs
• Language Institute
• Language Sciences
• Law -​ School-​Wide
• Life Sciences Communication
• Management and Human Resources
• Materials Science and Engineering
• Mathematics
• Mead Witter School of Music
• Mechanical Engineering
• Medical Physics
• Medicine and Public Health -​ School-​Wide
• Nuclear Engineering and Engineering Physics
• Nursing -​ School-​Wide
• Nutritional Sciences
• Operations and Information Management
• Pharmacy -​ School-​Wide
• Planning and Landscape Architecture
• Plant and Agroecosystem Sciences
• Plant Pathology
• Political Science
• Population Health Sciences
• Real Estate and Urban Land Economics
• Rehabilitation Psychology and Special Education
• Religious Studies
• Risk and Insurance
• Sandra Rosenbaum School of Social Work
• Soil and Environmental Sciences
• Soil Science
• Spanish and Portuguese
• Veterinary Medicine -​ School-​Wide
• Nondegree/​Visiting Student Guide
• Pharmacy Guide
• School of Medicine and Public Health Guide
• Undergraduate Guide
• Veterinary Guide